Affiliation:
1. Research Institute of Molecular Biology and Medicine at the National Center of Cardiology and Therapy Named After acad. M. Mirrakhimov.
2. Kyrgyz State Medical Academy named after I. K. Akhunbaev; Kyrgyz Russian Slavic University named after the First President of Russia B. N. Yeltsin.
3. Sechenov First Moscow State Medical University (Sechenov University).
Abstract
Steady increase in the prevalence of chronic kidney disease (CKD) is a serious public health problem, since CKD potentially leads to the development of end-stage renal disease (ESRD) that requires high-cost replacement therapy and is closely associated with increased risk of developing cardiovascular diseases (CVD), which are the cause of death in most patients. Progression of renal dysfunction and development of CVD are significantly affected by hyper- and dyslipidemia. This review contains results of studies evaluating the effect of hypolipidemic therapy on reduction of cardiovascular risk and slowdown of renal dysfunction in patients with CKD at pre-dialysis and dialysis stages of renal failure, as well as in patients with kidney transplant. In addition, recommendations on nutrition and new therapeutic approaches to lipid-lowering therapy in patients with CKD, as well as prospects for the usage of new hypolipidemic drugs are also presented.
Publisher
APO Society of Specialists in Heart Failure
Subject
Cardiology and Cardiovascular Medicine
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献